A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Healthy Subjects (Part A and B) * Healthy subjects, as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations * Subjects must be willing and able to complete all study-specific procedures and visits * Additional criterion for Japanese subjects in Groups BJ1 to BJ3: Subjects must be first generation Japanese (born in Japan and not living outside of Japan for \> 10 years, and both parents are ethnically Japanese) Heart Failure Patients (Part C) * Left ventricular EF \<45% and \>25%, as assessed by cardiac MRI within 3 months of first dose of study drug; or left ventricular EF \<40% and \>25% as assessed by echocardiogram at Screening or within 3 months of first dose of study drug; left ventricular EF * Heart failure is considered to be stable at the discretion of the Investigator (i.e., no acute cardiovascular \[CV\] events or hospitalization (including emergency room visits) for CV causes within 3 months of first dose of study drug * Regular sinus rhythm at Screening and no history of atrial fibrillation in the past 12 months Exclusion Criteria: Healthy Subjects (Part A and B) * Major surgery within 4 weeks of (first) study treatment administration * Inability to be venipunctured and/or tolerate venous access * Subjects who have smoked or used smoking cessation or nicotine containing products (including, but not limited, to e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum, varenicline, bupropion) within 6 months of the first dose of study drug Heart Failure Patients (Part C) * Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption * Major surgery within 4 weeks of (first) study treatment administration * Inability to be venipunctured and/or tolerate venous access Other protocol defined inclusion/exclusion criteria could apply